Business
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on
About this update from Mustang Bio, Inc.
[{"type":"text","content":"WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that an abstract reporting on Phase 1 trials being conducted at the University of Alabama at Birmingham (UAB) and City of Hope of Mustang Bio’s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma (GBM), has been selected as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana. The abstract will also be published in the online Proceedings of the AACR. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We look forward to the upcoming data to be presented by City of Hope’s Dr. Christine Brown at the AACR Annual Meeting about the potential of our MB-108 oncolytic virus to enhance the efficacy of our MB-101 CAR T cell therapy for GBM. Each program is actively enrolling patients in respective investigator-sponsored UAB and City of Hope Phase 1 trials, and we believe that the clinical data from those trials, together with results from the in vivo combination studies currently underway at City of Hope, will support the first ever industry-sponsored trial of an oncolytic virus with a CAR T for the treatment of cancer patients. Mustang will refer to the combination therapy as MB-109, and we anticipate filing an Investigational New Drug application for MB-109 later this year.” Details of the presentation are as follows: Title: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastomaAbstract Number: CT541Session Title: Phase I Trials in Progress 2Session Date and Time: Wednesday, April 13, 2022 from 9 a.m. – 12 p.m. CTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35Poster Board Number: 19Presenter: Christine Brown, Ph.D., Deputy Director, T Cell Therapeutics Research Laboratory, Professor, Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology and The Heritage Provider Network Professor in Immunotherapy at City of Hope, ...